New Pill-Immunotherapy combo takes on tough breast cancer
NCT ID NCT04176848
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 37 times
Summary
This phase 2 trial is testing whether combining an experimental pill (CFI-400945) with an immunotherapy drug (durvalumab) can shrink tumors in 15 women with advanced triple negative breast cancer that has spread or cannot be removed. The study measures how many participants see their tumors shrink or stabilize. It is currently active but no longer recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BCCA - Cancer Centre for the Southern Interior
Kelowna, British Columbia, V1Y 5L3, Canada
-
Juravinski Cancer Centre at Hamilton Health Sciences
Hamilton, Ontario, L8V 5C2, Canada
-
Kingston Health Sciences Centre
Kingston, Ontario, K7L 2V7, Canada
-
Ottawa Hospital Research Institute
Ottawa, Ontario, K1H 8L6, Canada
-
University Health Network
Toronto, Ontario, M5G 2M9, Canada
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CFI-400945 (a pill) and durvalumab (an immunotherapy drug)
What this could lead to
If it works, this combination could shrink tumors or slow disease progression in people with advanced triple negative breast cancer who have few other options.
What could go wrong
This is a small, early-phase trial with only 15 participants, so results may not apply to everyone. Side effects from the drugs could be serious, and the combination may not work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.